iBio, Inc. Common Stock
IBIOStock
$1.35+97.27%52W
Market Cap$71.04M
P/E—
Div yield—
Beta1.29
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-43.56%
Price vs S&P 500 (4W)-8.34%
VGM Score33.19
Market Capitalization$71.04M
Earnings Surprise History
Q3 26-0.06est. -0.06
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.25
4.25
4.25
4.21
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IBIOiBio, Inc. Common Stock | D | F | C | $1.35 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
iBio Inc is a preclinical-stage biotechnology company that uses artificial intelligence to develop precision antibodies and provide contract manufacturing services. The company's AI-driven platform employs epitope-steering and monoclonal antibody optimization to reduce development risk and accelerate time to clinic.